Mesoblast

Update in progress

MESO (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Mesoblast Limited and its subsidiaries develop regenerative medicine products based on mesenchymal lineage cells. Its lead product, Remestemcel-L, is in Phase III trials for systemic inflammatory diseases, including steroid-refractory acute graft-versus-host disease and inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease, and for chronic heart failure and degenerative low back pain. It also develops MPC-300-IV. Partnerships include Tasly, JCR Pharmaceuticals, and Grünenthal. Based in Melbourne, 2004.

Company score

Sentiment: 0.51; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.40; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.14; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.33; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationAustralia
CEODr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Founded2004
Employees81
Websitewww.mesoblast.com

Identifiers

ISINUS5907171046
FIGIBBG000QD6LZ1
LEI529900J5ALF3JG921927
CUSIP590717104
CIK0001345099